Citation Information :
Doshi K, Varghese A, Badyal DK. Evaluation of Omeprazole in the Treatment of Laryngopharyngeal Reflux Disease: A Single Center, Prospective and Randomized Study. Int J Otorhinolaryngol Clin 2015; 7 (2):45-50.
To assess efficacy and safety of omeprazole in laryngitis due to laryngopharyngeal reflux disease (LPRD).
Materials and methods
It was a prospective, randomized, open label study conducted in 90 patients with laryngitis due to LPRD. Group A (n = 45) received omeprazole and advice about life style modification, group B (n = 45) received only advice about life style modification. Reflux symptom index (RSI), reflux finding score (RFS), quality of life (QoL) and voice handicap index (VHI) were evaluated at 0, 4 and 8 weeks.
Results
P ercentage r eduction i n R SI a nd R FS w as s ignificantly higher in group A after 8 weeks (37 vs 29%, 18 vs 13% respectively). Excess throat mucus, clearing of throat and erythema of posterior larynx improved considerably in group A compared to group B.
Conclusion
Omeprazole could be a significant addition to life style modification in LPRD patients particularly for signs and symptoms, such as excess throat mucus, clearing of throat and erythema of posterior larynx.
How to cite this article
Doshi K, Varghese A, Badyal DK. Evaluation of Omeprazole in the Treatment of Laryngopharyngeal Reflux Disease: A Single Center, Prospective and Randomized Study. Int J Otorhinolaryngol Clin 2015;7(2):45-50.
Metaanalysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003;17(10):1237–1245.
Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized and double-blind study. Laryngoscope 2001;111(12):2147–2151.
Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116(2):254–260.
Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial. Clin Gastroenterol Hepatol 2010;8(9):770–776.
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 2001;96(4):979–983.
Proton pump inhibitors versus placebo in the treatment of LPR: a meta-analysis of nine RCTs. Otolaryngol Head Neck Surg 2013;149:P88–P88.
Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III and pepsin. Ann Otol Rhinol Laryngol 2005;114(12):913–921.
Laryngeal mucosa: its susceptibility to damage by acid and pepsin. Laryngoscope 2010;120(4):777–782.
New Delhi, India 2006. Available at: http://icmr.nic.in/ethical_guidelines.pdf. Accessed on 09/04/2015.
J Am Med Assoc 2013;310(20):2191–2194.
Development and validation of the voice handicap index-10. Laryngoscope 2004;114(9):1549–1556.
Short, self-report voice symptom scales: psychometric characteristics of the voice handicap index-10 and the vocal performance questionnaire. Otolaryngol Head Neck Surg 131(3):232–235.
The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991;101 101(4 Pt 2 Suppl 53):1–78.
GERD-induced ENT symptoms: a prospective placebo controlled study with omeprazole 40 mg a day. Gastroenterol 120(5):A16.
Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled doubleblind crossover study. Scand J Gastroenterol 2003;38(5):462–467.
Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology—head and neck surgery. Otolaryngol Head Neck Surg 2002;127(1):32–35.
Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg 2004;131(4):342–350.